AstraZeneca AZN0.60%increase; green up pointing triangle plans to spend GBP650 million ($828.8 million) on vaccine programs and various other initiatives in the U.K. The pharmaceutical company ...

Additionally, we have even greater US investment in manufacturing and R&D planned, leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA. Overall, we are making excellent progress ...

AstraZeneca succeeded in thwarting Pfizer's takeover plans – but was forced to promise investors that it could deliver very rapid growth – forecasting revenues of $45 billion by 2023, compared ...

AstraZeneca is bolstering its US manufacturing ... leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA.’ Soriot also told reporters the drugmaker will maintain its 2025 ...

CAMBRIDGE, Britain (AP) — CAMBRIDGE, Britain (AP) — Astrazeneca PLC (AZN) on Tuesday reported first-quarter profit of $2.92 billion. On a per-share basis, the Cambridge, Britain-based company ...

The Cambridge-based pharmaceutical company behind a variety of medicines paid its chief executive Pascal Soriot £14.7 million in 2024. The chief executive of drugmaker AstraZeneca was handed a pa ...

[CAMBRIDGE, UK] Drugmaker AstraZeneca said on Monday (Mar 17) it will buy biotechnology firm EsoBiotec for up to US$1 billion. EsoBiotec’s Engineered NanoBody Lentiviral (ENaBL) platform can ...

Pascal Soriot, Chief Executive Officer, AstraZeneca, said ... leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA. Overall, we are making excellent progress toward our ambition ...